Chief Commercial Officer

Regulatory actions for June 6, 2025

EC approves Santen’s Ryjunea to slow progression of pediatric myopia

EC approves Santen’s Ryjunea to slow progression of paediatric myopia

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Senior Director, Digital Marketing & Innovation

Sydnexis Inc. is a clinical-stage biopharmaceutical company focused on improving pediatric eye health through innovative solutions. The Senior Director of Digital Marketing will lead the development and implementation of digital marketing strategies to enhance customer engagement and drive innovation in marketing efforts.

Sign up with Google

Sign in with Google